Analyst Expectations for TG Therapeutics's Future
Portfolio Pulse from Benzinga Insights
In the last quarter, TG Therapeutics (NASDAQ:TGTX) received 5 bullish and 1 somewhat bullish analyst ratings. The average 12-month price target for the company is $30.25, with a high of $37.50 and a low of $24.00. The average price target has increased by 16.35% over the past month.
May 31, 2023 | 6:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TG Therapeutics received positive analyst ratings, with an average 12-month price target of $30.25, which has increased by 16.35% over the past month.
The positive analyst ratings and the increase in the average 12-month price target over the past month indicate a bullish sentiment towards TG Therapeutics. This is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100